NIAID Site Search

NIAID supports a wide range of vector-related research, including activities to better understand the process of transmission of pathogens via arthropod (insects and ticks) vectors. As part of this effort, NIAID brings together a multidisciplinary group of investigators from the fields of vector biology, parasite immunology, and vertebrate host immunology to dissect the complex process of pathogen transmission at the intersection of the human host, the arthropod vector, and the pathogen.

Last Reviewed: September 6, 2022

Project Title: Genetic Determinants of Susceptibility to Severe COVID-19 Infection NIAID Principal Investigator: Helen Su, M.D., Ph.D Chief, Human Immunological Diseases Section, LCIM Why does COVID-19 cause only mild or no illness in some individuals, but severe or deadly disease in others? The Human Immunological Diseases Section of the Laboratory of Clinical Immunology & Microbiology (LCIM)

Last Reviewed: April 24, 2020

The objective of this study is to learn how Staphylococcus aureus (S. aureus) interacts with cells in the body using tissues from tonsils discarded after standard surgery to remove them.

The Laboratory of Host Immunity and Microbiome (LHIM) at NIAID comprehensively examines the factors controlling immunity and inflammation.

Last Reviewed: February 18, 2025

This purpose of this protocol is to evaluate selected patients with documented recurrent or unusual infections and their family members for clinical and laboratory correlates of immune abnormalities.

The objective of this study is to collect samples and data from individuals who have been exposed to or have contracted viral infections.

The COVID-19: How SARS-CoV-2 binds to host cells module is part of the Pathogens in Augmented Reality (PathogenAR) mobile app. COVID-19 is a severe respiratory infection caused by the SARS-CoV-2 virus. In order to infect host cells, SARS-CoV-2 has a surface protein which can specifically bind to another surface protein on host cells. Disrupting this interaction is key to several vaccines and

Last Reviewed: February 3, 2021

The purpose of this study is to collect microbiome samples from the body that can be used for future research.

This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment.

It’s a finding perfect for spooky season—inside a bloodsucking insect, a parasite uses the blood of mammals to get more fit to infect unsuspecting people. In this case, the story is more troubling because it’s a real threat. The parasite is Leishmania, which causes leishmaniasis, a primarily tropical and subtropical disease that can cause skin lesions and organ damage, and can be fatal.

Published: October 25, 2023

The purpose of this study is to see how Bismuth subsalicylate (BSS) affects gut bacteria in healthy people.

The purpose of this study is to determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors.

Information about the various areas of malaria research supported by NIAID including the full cycle of malarial disease.

Last Reviewed: March 4, 2016

This NIH Strategic Plan for Tickborne Disease Research proposes building on current trans-NIH efforts to better understand the complex interplay among host, tick, and pathogen factors that contribute to TBDs and the body’s defenses against them.

Last Reviewed: May 7, 2025

The NIAID strategic updated plan is structured around four strategic priorities that are critical to the development and evaluation of the knowledge and tools needed to end TB globally.

Last Reviewed: May 1, 2025

To protect people against Coccidioides infection, the NIAID Strategic Plan for Research to Develop a Valley Fever Vaccine reflects the NIAID research priorities for developing a Valley fever vaccine.

Last Reviewed: May 1, 2025

The Strategic Plan for NIH Research to Cure Hepatitis B 2022 Update reaffirms NIH’s commitment to the vision and mission outlined in the 2019 strategic plan to end the hepatitis B epidemic by developing a cure and improving vaccination, screening, and follow-up to care.

Last Reviewed: May 1, 2025

To advance research to understand and address HSV infection, the NIH has established the Strategic Plan for Herpes Simplex Virus Research. This plan aligns with ongoing national efforts.

Last Reviewed: May 1, 2025

Sample grant application from Stephen Dewhurst, Ph.D., for exploratory with possible transition to expanded development grant (R21/R33).

Last Reviewed: April 21, 2025

Lenette Lu, M.D., Ph.D., of the Massachusetts General Hospital K08 sample application

Last Reviewed: March 31, 2025

Tuan Manh Tran, M.D., Ph.D., of the Indiana University-Purdue University at Indianapolis K08 sample application

Last Reviewed: March 31, 2025

Nico Contreras, Ph.D., of University of Arizona, F31 sample application

Last Reviewed: March 31, 2025

Stella Kakeeto, M.B.A., Makerere University G11 sample application

Last Reviewed: March 31, 2025

Lilliam Ambroggio, Ph.D., of the Cincinnati Children’s Hospital Medical Center K01 sample application

Last Reviewed: March 31, 2025

Last Reviewed: March 31, 2025